People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Pharmaceuticals, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Jaguar Health, Inc. | — | Pharmaceuticals | Series C | $151.1M | $58.9M | 2017 |
| Neuraltus Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $40.6M | $462.7M | 2009 |
| Aquyre Biosciences Inc | — | Biotech / Pharma | Series B | $28.6M | $31.1M | 2022 |
Ari Azhir at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ari Azhir on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Walker | 1 | 17 |
| Terry Gould | 1 | 6 |
| Steven King | 1 | 6 |
| James J. Bochnowski | 1 | 5 |
| Jonathan Siegel | 1 | 5 |
| Thierry Thaure | 1 | 5 |
| Anula Jayasuriya | 1 | 5 |
| James Bochnowski | 1 | 4 |
| James Woody | 1 | 4 |
| Annette Bianchi | 1 | 4 |
| John Kallassy | 1 | 4 |
| Pravin Chaturvedi | 1 | 4 |
| Lisa Conte | 1 | 3 |
| James N. Woody | 1 | 3 |
| Serge Martinod | 1 | 3 |
| Zhi Yang | 1 | 2 |
| Charles Thompson | 1 | 2 |
| Jonathan Wolin | 1 | 2 |
| Carol Lizak | 1 | 2 |
| John Whelan | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.